Spain inaugurates hybrid quantum infrastructure, the EU Chips Act prepares a demand-side pivot, and Vega-C flies again. Three structural bets that landed this week.
Lead
Barcelona's Quantum Infrastructure Bet Lands
Spain's Barcelona Supercomputing Center inaugurated an analog quantum computer from Qilimanjaro Quantum Tech on May 28, making BSC one of a handful of facilities globally where analog quantum, digital quantum, and classical supercomputing operate as a unified hybrid system. The €10 million EuroQCS-Spain installation is backed by the EuroHPC Joint Undertaking and Spain's SEDIA, with two further hardware generations scheduled through 2027.
This is not a research prototype. It is shared infrastructure open to European researchers and industry, built to run optimisation problems in pharma, logistics, finance, and AI that current classical systems handle poorly. The test now is whether European research groups converge on BSC as a serious compute destination, or whether the installation remains an infrastructure milestone without the workload to match.
(Qilimanjaro) (Euronews)
Biotech & Life Sciences
EU Biotech Act at 100 Days: FAST-EU Now Operational
The EU Biotech Act proposal hit its 100-day mark this week, with legal commentary confirming that full legislative adoption is not expected before end-2026. The FAST-EU pilot, which targets multinational clinical trial approval times of 76 days (down from 105), became operational in January and is now processing its first applications. Early signals suggest sponsors are using the voluntary pathway.
The structural question remains open: a 76-day EU target still trails FDA timelines under comparable conditions, and US biotech raised capital in 2025 at roughly ten times the European rate. FAST-EU is a meaningful reform, but it is one instrument in a much larger competitiveness gap.
Complement Therapeutics Doses First Patient in CTx001 Gene Therapy Trial
Munich-based Complement Therapeutics dosed the first patient in Opti-GAIN, its Phase I/II study of CTx001, an AAV-based gene therapy for geographic atrophy secondary to AMD, in late March. Geographic atrophy affects 5 million people globally; CTx001 targets the complement cascade with a single subretinal injection, aiming for durable effect where current anti-VEGF treatments require indefinite repeat visits.
The trial is international and carries FDA Fast Track designation. It is one of several European-origin gene therapies entering the clinic in 2026, reflecting genuine depth in AAV platforms across German and Swiss research groups, even as the commercial pathway for approved gene therapies in Europe remains fragile.
Quantum & Photonics
Jülich Sets World Record: 50-Qubit Simulation on JUPITER
Scientists at Jülich Supercomputing Centre, working with NVIDIA, used Europe's JUPITER exascale supercomputer to fully simulate a 50-qubit quantum computer, surpassing the previous record of 48 qubits set at the same centre in 2019. The result demonstrates how classical HPC can benchmark and validate quantum hardware without requiring physical systems at scale.
It also sharpens a boundary question: at what qubit count does simulation advantage break down entirely? JUPITER can push that ceiling, but Europe needs quantum hardware development to stay ahead of where simulation runs out.
Space
Vega-C Returns to Flight with Smile
The Smile mission lifted off on Vega-C from Kourou on May 19. It was the rocket's second successful flight since its December 2022 failure grounded it for over three years. Smile is a joint ESA and Chinese Academy of Sciences mission that will use X-ray and ultraviolet instruments to observe Earth's magnetosphere and its response to solar wind, including 45-hour continuous aurora observations.
The Vega-C return carries significance beyond the science payload. European commercial launch capacity has been constrained since Ariane 5's retirement, and Ariane 6's pace has remained below commercial demand. Each successful Vega-C flight reduces that pressure modestly. First signal confirmed at 06:48 CEST via ESA's New Norcia ground station in Australia.
(ESA)
Materials & Manufacturing
Uplift360 Raises €7.4M to Regenerate Defense Composites
Bristol-based Uplift360 closed a €7.4M seed round, backed in part by the NATO Innovation Fund, to build its first pilot-scale production line for chemically regenerated composite materials. Its ChemR process restores carbon fibre and aramid laminates recovered from Eurofighter Typhoon components to virgin-fibre performance standards. Customers include Rolls-Royce, Babcock, and Leonardo.
The European defense and aerospace sector generates substantial composite waste as legacy aircraft retire. Uplift360's proposition is strategic: virgin-grade recovered carbon fibre reduces dependence on imported feedstocks and shortens supply chains that geopolitical pressure has proved capable of disrupting.
Robotics & Automation
NEURA Robotics Closes €1 Billion Series C
Metzingen-based NEURA Robotics closed approximately €1 billion in a Series C backed by Tether Holdings, valuing the company at €4 billion. Schaeffler has committed to integrating thousands of NEURA robots into its global manufacturing network by 2035. HD Hyundai is piloting NEURA humanoid and quadruped robots in shipbuilding operations.
Europe holds less than 3% of disclosed capital in the global humanoid robotics market. NEURA is the exception: a European-origin company that has competed on valuation with US and Chinese peers. Converting deployment partnerships into recurring commercial contracts is the next test.
Semiconductors
Chips Act 2.0 Pivots to Demand, and Admits the Gap
The European Commission is set to publish a revised Chips Act on June 3. Reporting this week confirmed the €120 billion public-private investment target by 2035 and revealed the draft's core shift: from supply-side manufacturing subsidies toward demand aggregation, procurement coordination, and consumption incentives to pool European industrial chip demand, particularly for AI.
The pivot is an admission. A Bruegel analysis published in May concluded the original Act "has underdelivered," with €13.75 billion in State aid approved by early 2026, against more than €30 billion in US CHIPS Act grants already deployed. Germany received €288 million in State aid approval on May 20 for first-of-a-kind semiconductor facilities. The demand-side theory requires European industrial chip consumption to be coherent enough to aggregate. That is the structural question the June 3 text will need to answer.
One to Watch
ERC+ Super Grants: The First Call Opens
The European Research Council opened its first ERC+ call on May 28, introducing a seven-year €7 million grant for researchers at any career stage and in any field. The evaluation is interview-driven, assessing long-range scientific vision rather than technical detail.
The structural stakes are real. Standard ERC formats have historically rewarded incremental safety in proposals; ERC+ is designed for the kind of high-risk, decade-long bets that define deep tech trajectories. Watch whether the first cohort attracts researchers in quantum materials, synthetic biology, and advanced manufacturing who have struggled to fit genuinely ambitious proposals into existing grant formats. The call closes in autumn 2026.
(ERC)